Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone."One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scientific Officer at...
Calgary, Alberta--(Newsfile Corp. - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes ForVotes WithheldPercent ForPercent WithheldDonald J....
Calgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the "Transaction") with an arm's length subscriber (the "Subscriber"). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.